A practical reference on Allergenicity testing: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Regulatory and labeling frameworks vary by country. In the United States, whey protein hydrolysate may be regulated as a food ingredient or a dietary supplement ingredient depending on intended use. In the European Union, it falls under general food law, with additional rules for infant formula and foods for special medical purposes. A claim of hypoallergenicity is not established by hydrolysis alone and generally requires clinical evidence. Open questions remain about how degree of hydrolysis relates to bitterness, nitrogen absorption, and residual allergenicity across different products and processing methods.
Quality control for whey protein hydrolysate combines compositional and molecular tests. Protein content is measured by Kjeldahl or Dumas nitrogen determination. Moisture, ash, fat, and lactose are checked with standard food methods. The degree of hydrolysis is estimated by TNBS, OPA, or pH-stat procedures that quantify free amino groups or released protons. Molecular weight distribution is examined by size-exclusion chromatography or SDS-PAGE. These tests describe average peptide size rather than exact peptide sequences, and results depend on standards and calibration.
Storage stability depends on moisture, temperature, oxygen, and packaging, and hydrolysates are hygroscopic and can cake when exposed to humid air. Maillard reactions between peptides and residual lactose can cause browning and flavor changes during warm storage, while lipid oxidation may develop if residual fat is present. Cool, dry conditions and sealed containers slow these reactions. Shelf-life studies typically monitor moisture, color, solubility, molecular weight profile, and microbial counts over time. Accelerated tests estimate stability, but real-time data remain the reference for shelf-life assignment.
Regulatory status differs by country and intended use. In many jurisdictions, whey protein hydrolysate is regulated as a food ingredient, while specific infant formula or medical food uses may require additional review. Labeling rules govern protein content claims, allergen statements, and terms such as partially hydrolyzed or extensively hydrolyzed. Analytical methods for degree of hydrolysis are not fully standardized, so values can depend on the assay. This variability makes direct comparison between products difficult unless the method and reference material are stated.
| Property | Value | Notes |
|---|---|---|
| Protein determination | Kjeldahl nitrogen × 6.38 | Dumas combustion also used |
| Degree of hydrolysis | TNBS, OPA, or pH-stat | Results method-dependent |
| Molecular weight distribution | SEC-HPLC or SDS-PAGE | Reports ranges, not sequences |
| Residual lactose | Enzymatic or HPLC | Relevant for low-lactose products |
| Microbiological limit | Total plate count < 10^4 CFU/g | Typical internal specification, varies |
Commercial production begins with whey protein concentrate or isolate dissolved in water. A protease is added under controlled pH and temperature, and the reaction is stopped by heat or pH adjustment once a target degree of hydrolysis is reached. Membrane filtration, often ultrafiltration or diafiltration, removes enzymes and small solutes while retaining peptides. The liquid is then concentrated and spray-dried into a powder. Each step influences peptide length, mineral content, and flavor.
Quality control focuses on degree of hydrolysis, molecular weight distribution, protein content, moisture, ash, and microbial limits. Degree of hydrolysis is commonly calculated from the number of cleaved peptide bonds relative to total peptide bonds. Size-exclusion chromatography and mass spectrometry can describe peptide size ranges, while amino acid analysis quantifies composition. Standard methods from dairy science organizations are often used, though no single method captures every functional property. Results are therefore reported alongside processing conditions.
Industrial production begins with whey protein concentrate or isolate dispersed in water. Selected proteases, such as trypsin, pepsin, or microbial enzymes, are added under controlled pH and temperature. Hydrolysis continues until a target hydrolysis level is reached, after which heat or pH adjustment inactivates the enzyme. Ultrafiltration, diafiltration, and ion exchange may remove larger peptides, salts, or residual lactose. The liquid is then concentrated and spray-dried into powder. Processing choices influence peptide size, bitterness, mineral content, and microbial quality.
Analytical control focuses on protein content, hydrolysis extent, molecular weight distribution, and residual intact protein. Kjeldahl or Dumas methods measure total nitrogen, while size-exclusion chromatography or mass spectrometry estimates peptide profiles. Sodium dodecyl sulfate polyacrylamide gel electrophoresis can show remaining intact proteins, though small peptides may not resolve. Enzyme-linked immunosorbent assays are used to assess residual allergenic proteins in some contexts. Because no single method captures all relevant features, manufacturers combine several assays and report values against internal specifications.
Stability depends on moisture, temperature, oxygen, and packaging. Powdered hydrolysate generally requires cool, dry storage and protection from humidity because peptides can absorb water and undergo Maillard reactions with residual lactose. Higher temperatures can increase bitterness, discoloration, and loss of solubility over time, while liquid hydrolysate formats are more perishable and may need refrigeration or preservatives. Shelf-life studies typically monitor moisture, color, pH, protein solubility, and microbial counts. Exact stability limits vary by peptide profile, packaging, and water activity, so general rules should be treated as approximate.
Laboratories characterize whey protein hydrolysate using several complementary methods. Nitrogen determination estimates total protein, while size-exclusion chromatography and mass spectrometry reveal peptide size distributions. Degree of hydrolysis can be calculated from free amino groups, pH change, or osmolarity, but each approach has assumptions. Moisture, ash, and mineral content are also measured because they affect shelf life and reconstitution. No single test fully describes a hydrolysate, so specifications usually combine several results.
Storage stability depends on moisture, temperature, and exposure to oxygen. Dry hydrolysate powders are hygroscopic and can clump or cake when humidity is high. Moisture also promotes Maillard reactions between peptides and residual lactose, leading to browning and flavor changes. Cool, dry, sealed storage slows these reactions, while prolonged warmth can increase off-flavors and reduce solubility. Stability studies often track color, moisture, free amino groups, and microbial load over time to estimate shelf life.
Quality control for hydrolyzed whey protein focuses on composition, peptide size, and batch consistency. Protein content is commonly measured by Kjeldahl or combustion analysis, while moisture and ash are determined by gravimetric methods. Peptide molecular weight distribution is often assessed by size exclusion chromatography or mass spectrometry. The extent of hydrolysis can be estimated by titration, trinitrobenzenesulfonic acid assays, or formol titration. Because hydrolysis produces a complex mixture, no single test captures every relevant property, and laboratories often combine several methods.
Allergen testing is relevant because whey is a milk-derived ingredient. Immunoassays can detect residual milk proteins, but hydrolysis may alter or destroy antibody-binding sites, leading to false negatives or underestimation. Liquid chromatography with tandem mass spectrometry can identify specific peptide markers and is less dependent on intact protein epitopes. Regulatory labeling rules for milk allergens vary by country, and a product described as hydrolyzed is not automatically exempt from allergen declaration. For infants, specialized formulas require strict control of protein molecular weight and sterility, which adds testing beyond routine composition.
One of the challenges of in vitro modelling of complex tissues is the difficulty of co-culturing different cell types. Co-culturing of different cell types can be achieved at the onset of levitation, either by mixing different cell types before levitation, or by magnetically guiding 3D cultures in an invasion assay format. Co-culturing in a realistic tissue architecture is important for accurately modeling in-vivo conditions. One example is increasing the accuracy of cellular assays, as shown in the figure on the right. In the figure, the human GBM cells and normal human astrocytes (NHA) are cultured separately and then magnetically guided together (left, time 0). Invasion of GBM into NHA in 3D culture provides an assay for basic cancer biology and drug screening (right, 12h to 252h). Magnetic levitation has shown potential for maintaining cell viability and simulating in vivo conditions. However, its scalability and efficacy in comparison to traditional culturing methods have been topics of discussion.
Hydrogel from wood-based nanofibrillated cellulose (NFC) is used as a matrix for 3D cell culture, providing a three-dimensional environment that more closely resembles the conditions found in living tissue. As plant based material, it does not contain any human- or animal-derived components. Nanocellulose is instead derived from wood pulp that has been processed to create extremely small, nanoscale fibers. These fibers can be used to create a hydrogel, which is a type of material that is made up of a network of cross-linked polymer chains and is able to hold large amounts of water. As the natural extracellular matrix (ECM) is important in the survival, proliferation, differentiation and migration of the cells, hydrogels mimicking natural ECM structure are considered as potential approaches towards in vivo –like cell culturing.
CooA is a homodimeric, heme-containing transcription factor of the CAP/CRP family, with each monomer comprising an N-terminal heme-binding regulatory domain and a C-terminal helix-turn-helix motif that acts as a DNA-binding domain. The N-terminal domain coordinates a b-type heme whose axial ligands differ between species (for example, His-Pro versus His-His), and carbon monoxide (CO) binding to this heme triggers conformational changes that activate DNA binding. The two subunits associate through a coiled-coil-like interface, positioning the paired helix–turn–helix motifs to recognize target palindromic sequences in promoter DNA and thereby regulate genes involved in CO oxidation. Several structures of CooA have been solved, including: RrCooA in the ferrous state (1FT9), ChCooA in the ferrous, imidazole-bound state (2FMY), ChCooA in the ferrous, CO-bound state (2HKX).
17. Adv Gerontol. 2014;27(3):399-406. [Peptides and CCL11 and HMGB1 as molecular markers of aging: literature review and own data]. [Article in Russian] Khavinson VKh, Kuznik BI, Tarnovskaia SI, Lin'kova NS. Cytokines CCL11 (eotaxin) and HMGB1 (alarmin1) are molecular markers of ageing and neurological, cardiovascular and immune diseases. Created in St. Petersburg Institute of Bioregulation and Gerontology short peptides are known to regulate gene expression and protein synthesis. They promote the mortality decrease and slowdown the development of pathology in the elderly. The article presents the proposed role of dipeptide vilon (Lys-Glu) and tetrapeptide epitalon (Ala-Glu-Asp-Gly) in CCL11 and HMGB1 genes regulation as activators of their expression. Geroprotective action of vilon and epitalon probably realizes in suppression of these genes.
Sources: en.wikipedia.org
Brenipatide (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code name LY-3537031) is a dual agonist of glucagon-like peptide-1 (GLP-1) receptors and gastric inhibitory polypeptide (GIP) receptors. Brenipatide is under development by Eli Lilly and Company for the treatment of alcoholism, bipolar disorder, asthma, smoking withdrawal, cardiovascular disorders, liver disorders, metabolic disorders, and obesity. It is taken by subcutaneous injection once per month. The drug has a longer elimination half-life than tirzepatide or retatrutide. As of December 2025, it was in phase 3 clinical trials for alcoholism and bipolar disorder, phase 2 trials for asthma and smoking withdrawal, and phase 1 trials for cardiovascular disorders, liver disorders, metabolic disorders, and obesity. List of investigational antipsychotics List of investigational bipolar disorder drugs List of investigational substance-related disorder drugs
Sampling provides one rational means of verification that a production lot conforms to the requirements of technical specifications. 100% inspection does not guarantee 100% compliance and is too time-consuming and costly. Rather than evaluating all items, a specified sample is taken, inspected or tested, and a decision is made about accepting or rejecting the entire production lot. Sampling plans have known risks: an acceptable quality limit (AQL) and a rejectable quality level, such as lot tolerance percent defective (LTDP), are part of the operating characteristic curve of the sampling plan. These are primarily statistical risks and do not necessarily imply that a defective product is intentionally being made or accepted. Plans can have a known average outgoing quality limit (AOQL). A single sampling plan for attributes is a statistical method by which the lot is accepted or rejected on the basis of one sample. Suppose that we have a lot of sizes M {\displaystyle M} ; a random sample of size N < M {\displaystyle N<M} is selected from the lot; and an acceptance number B
For homozygosity, the incidence is approximately 1:2,000-4,000, whereas the incidence for heterozygosity increases to up to 1:500. The variant EaEa genotype, homozygous absent, is approximately 1:3200. The gene for the dibucaine-resistant atypical cholinesterase appears to be widely distributed. Among Caucasians, males are affected almost twice as often as females. The frequency for heterozygosity is low among black people, Japanese and non-Japanese Asians, South Americans, Australian Aboriginal peoples, and Arctic Inuit (in general). However, there are a few Inuit populations (e.g., Alaskan Inuit) with an unusually high gene frequency for BChE deficiency. A relatively high frequency also was reported among Jews from Iran and Iraq, Caucasians from North America, Great Britain, Portugal, Yugoslavia, and Greece.
Sources: en.wikipedia.org
It is often estimated by TNBS, OPA, or pH-stat methods that quantify free amino groups or released protons. Values depend on assay conditions, protein standard, and calculation method. No single universal protocol exists for all products.
It shows the relative amounts of peptides in different size ranges, commonly by size-exclusion chromatography or SDS-PAGE. A lower average weight indicates more extensive hydrolysis. It does not identify specific peptide sequences or biological effects.
No. Immunoassays can measure residual protein or specific whey proteins, but hypoallergenicity requires clinical evaluation. Hydrolysis may reduce IgE-binding, yet some peptides can remain reactive. Label claims are regulated separately from analytical results.
Methods include trinitrobenzenesulfonic acid assay, o-phthaldialdehyde assay, formol titration, and nitrogen solubility. Values depend on calibration and assay conditions. Results should be interpreted with the stated method.